This clinical trial is studying how well magnetic resonance imaging (MRI) in combination with 18F-fluoromisonidazole (18F-FMISO) positron emission tomography (PET)/computed tomography (CT) scans works in assessing a decrease in the amount of oxygen (hypoxia) in tumor cells and in guiding adaptive radiation treatment in patients with head and neck cancer or cancer that has spread to the brain from where it first started (brain metastasis). Both head and neck cancer and brain metastases can be treated with radiation. Previous research studies have shown that the amount of oxygen that goes towards cancer cells prior to their radiation treatments predicts how the cancer cells will respond to radiation treatment. MRI is a type of imaging technique that uses radio waves and large magnets to produce detailed images of areas inside the body. 18F-FMISO is a radioactive substance that binds to hypoxic tumor cells and emits radiation, allowing the tumor cells to be visualized using PET/CT, which is an imaging technique that combines PET and CT in a single machine. It is used to make detailed, computerized images of inside the body. By combining MRI with 18F-FMISO PET/CT, researchers may be able to develop an MRI sequence that can be used to evaluate hypoxia in tumor cells and predict response to treatment in patients with head and neck cancer or brain metastases.
Additional locations may be listed on ClinicalTrials.gov for NCT05996432.
Locations matching your search criteria
United States
Tennessee
Nashville
Vanderbilt University/Ingram Cancer CenterStatus: Active
Contact: Jill De Vis
Phone: 615-936-8422
PRIMARY OBJECTIVE:
I. Validate non-invasive, MRI-based markers of tumor hypoxia in patients with brain metastases or head and neck cancer with and without evidence of tumor hypoxia identified by 18F-FMISO-PET-CT.
SECONDARY OBJECTIVES:
I. Assess treatment-related changes in tumor and peritumoral tissue oxygen consumption and perfusion via non-invasive MRI. (Head and Neck [H&N] Population)
II. Evaluate the effect of pre-treatment and post-treatment (3 months) tumor hypoxia on tumor recurrence, progression, and radiation necrosis in patients with central nervous system (CNS) metastases treated with standard of care (SOC) stereotactic radiosurgery (SRS). (CNS Metastasis Population)
OUTLINE: Patients are assigned to 1 of 2 groups.
GROUP I (H&N POPULATION): Patients undergo MRI over 60 minutes and receive 18F-FMISO intravenously (IV) and undergo PET/CT over 3 hours at screening and again 7-14 days into SOC radiation therapy (RT). Patients also undergo CT and FDG-PET/CT during screening and follow up.
GROUP II (CNS METASTASIS POPULATION): Patients undergo MRI over 60 minutes and receive 18F-FMISO IV and undergo PET/CT over 3 hours at screening and 3 months after SOC SRS. Patients also undergo SOC brain MRI and FDG-PET/CT during screening and follow up.
After completion of study intervention, participants are followed up for 2 years.
Trial PhaseNo phase specified
Trial Typediagnostic
Lead OrganizationVanderbilt University/Ingram Cancer Center
Principal InvestigatorJill De Vis